Next Generation Influenza Vaccines: Looking into the Crystal Ball

Overview

Journal Vaccines (Basel)

Date 2020 Aug 23

PMID 32825635

Citations 6

Authors

Carlos Alberto Guzman

Affiliations

Soon will be listed here.

Abstract

Influenza infections are responsible for significant number of deaths and overwhelming costs worldwide every year. Vaccination represents the only cost-efficient alternative to address this major problem in human health. However, current vaccines are fraught by many limitations, being far from optimal. Among them, the need to upgrade vaccines every year through a time-consuming process open to different caveats, and the critical fact that they exhibit poorer efficacy in individuals who are at high risk for severe infections. Where are we? How can knowledge and technologies contribute towards removing current roadblocks? What does the future offer in terms of next generation vaccines?

Citing Articles

The applications of live attenuated influenza a virus with modified NS1 gene.

Zhang H, Wang L, An Y, Chen Z Mol Ther Nucleic Acids. 2025; 36(1):102471.

PMID: 40046952 PMC: 11880705. DOI: 10.1016/j.omtn.2025.102471.

Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune Generate Broadly Protective Antibody Responses in Mice and Ferrets.

Allen J, Zhang X, Medina J, Thomas M, Lynch A, Nelson R Vaccines (Basel). 2025; 12(12.

PMID: 39772026 PMC: 11679666. DOI: 10.3390/vaccines12121364.

Longitudinal assessment of human antibody binding to hemagglutinin elicited by split-inactivated influenza vaccination over six consecutive seasons.

Carlock M, Allen J, Hanley H, Ross T PLoS One. 2024; 19(6):e0301157.

PMID: 38917104 PMC: 11198804. DOI: 10.1371/journal.pone.0301157.

mRNA vaccines encoding computationally optimized hemagglutinin elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses isolated between 2018-2020.

Allen J, Ross T Front Immunol. 2024; 15:1334670.

PMID: 38533508 PMC: 10963417. DOI: 10.3389/fimmu.2024.1334670.

Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Allen J, Ross T J Virol. 2022; 96(7):e0165221.

PMID: 35289635 PMC: 9006891. DOI: 10.1128/jvi.01652-21.

References

McLean K, Goldin S, Nannei C, Sparrow E, Torelli G . The 2015 global production capacity of seasonal and pandemic influenza vaccine. Vaccine. 2016; 34(45):5410-5413. PMC: 5357707. DOI: 10.1016/j.vaccine.2016.08.019. View

Iuliano A, Roguski K, Chang H, Muscatello D, Palekar R, Tempia S . Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2017; 391(10127):1285-1300. PMC: 5935243. DOI: 10.1016/S0140-6736(17)33293-2. View

Ebensen T, Debarry J, Pedersen G, Blazejewska P, Weissmann S, Schulze K . Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice. Front Immunol. 2017; 8:1223. PMC: 5624999. DOI: 10.3389/fimmu.2017.01223. View

Gaeta G, Stornaiuolo G, Precone D, Amendola A, Zanetti A . Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine. 2002; 20 Suppl 5:B33-5. DOI: 10.1016/s0264-410x(02)00510-8. View

Widjaja L, Ilyushina N, Webster R, Webby R . Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology. 2006; 350(1):137-45. DOI: 10.1016/j.virol.2006.02.020. View

Giles B, Ross T . A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 2011; 29(16):3043-54. PMC: 3090662. DOI: 10.1016/j.vaccine.2011.01.100. View

Brydak L, Machala M . Humoral immune response to influenza vaccination in patients from high risk groups. Drugs. 2000; 60(1):35-53. DOI: 10.2165/00003495-200060010-00004. View

Harding A, Heaton B, Dumm R, Heaton N . Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs. mBio. 2017; 8(3). PMC: 5461409. DOI: 10.1128/mBio.00669-17. View

Scorza F, Pardi N . New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines (Basel). 2018; 6(2). PMC: 6027361. DOI: 10.3390/vaccines6020020. View

10.

Principi N, Camilloni B, Alunno A, Polinori I, Argentiero A, Esposito S . Drugs for Influenza Treatment: Is There Significant News?. Front Med (Lausanne). 2019; 6:109. PMC: 6546914. DOI: 10.3389/fmed.2019.00109. View

11.

Clemens E, van de Sandt C, Wong S, Wakim L, Valkenburg S . Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine. Vaccines (Basel). 2018; 6(2). PMC: 6027237. DOI: 10.3390/vaccines6020018. View

12.

Petsch B, Schnee M, Vogel A, Lange E, Hoffmann B, Voss D . Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012; 30(12):1210-6. DOI: 10.1038/nbt.2436. View

13.

Lewnard J, Cobey S . Immune History and Influenza Vaccine Effectiveness. Vaccines (Basel). 2018; 6(2). PMC: 6027411. DOI: 10.3390/vaccines6020028. View

14.

Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D . Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2016; 35(4):513-520. DOI: 10.1016/j.vaccine.2016.12.011. View

15.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

16.

Lin Y, Wharton S, Whittaker L, Dai M, Ermetal B, Lo J . The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. Influenza Other Respir Viruses. 2017; 11(3):263-274. PMC: 5410720. DOI: 10.1111/irv.12447. View

17.

Zimmermann P, Curtis N . Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019; 32(2). PMC: 6431125. DOI: 10.1128/CMR.00084-18. View

18.

Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert A . The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. Respir Res. 2018; 19(1):123. PMC: 6013893. DOI: 10.1186/s12931-018-0784-1. View

19.

Harding A, Heaton N . Efforts to Improve the Seasonal Influenza Vaccine. Vaccines (Basel). 2018; 6(2). PMC: 6027170. DOI: 10.3390/vaccines6020019. View

20.

Riese P, Guzman C . Roads to advanced vaccines: influenza case study. Microb Biotechnol. 2017; 10(5):1036-1040. PMC: 5609253. DOI: 10.1111/1751-7915.12835. View